TCR2 THERAPEUTICS INC. Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Tcr2 Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2022.
  • Tcr2 Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2023 was -$40.4M, a 38.7% decline year-over-year.
  • Tcr2 Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2023 was -$163M, a 51.8% decline year-over-year.
  • Tcr2 Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$152M, a 52.1% decline from 2021.
  • Tcr2 Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$99.8M, a 48.7% decline from 2020.
  • Tcr2 Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$67.1M, a 41% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$152M -$52M -52.1% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-23
2021 -$99.8M -$32.7M -48.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$67.1M -$19.5M -41% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-22
2019 -$47.6M -$23.3M -96.3% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-16
2018 -$24.3M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.